Brought to you by 
SBIO grants Tragara rights to a new kinase inhibitor
04 May 2011
Executive Summary
Cancer therapeutics developer SBIO Pte. Ltd. has granted Tragara Pharmaceuticals (oncology and inflammation) exclusive worldwide rights to develop and commercialize its SB1317 for hematologic malignancies.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SBIO grants Tragara rights to a new kinase inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice